Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. - Wikidata - awgldk - TriplyDB

Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis.

Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis.

http://www.wikidata.org/entity/Q30438396

about

New progress in angiogenesis therapy of cardiovascular disease by ultrasound targeted microbubble destruction Nanoparticle delivery enhancement with acoustically activated microbubbles.Silk fibroin-based nanoparticles for drug delivery Drug and gene delivery across the blood-brain barrier with focused ultrasound Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion.The partitioning of nanoparticles to endothelium or interstitium during ultrasound-microbubble-targeted delivery depends on peak-negative pressure.In vivo imaging of microfluidic-produced microbubbles.Novel delivery approaches for cancer therapeutics.Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy.Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.Trans-illuminated laser speckle imaging of collateral artery blood flow in ischemic mouse hindlimb.Ultrasound contrast-enhanced imaging and in vitro antitumor effect of paclitaxel-poly(lactic-co-glycolic acid)-monomethoxypoly (ethylene glycol) nanocapsules with ultrasound-targeted microbubble destruction.Contrast ultrasound targeted treatment of gliomas in mice via drug-bearing nanoparticle delivery and microvascular ablation Covalently linking poly(lactic-co-glycolic acid) nanoparticles to microbubbles before intravenous injection improves their ultrasound-targeted delivery to skeletal muscle.Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.Potential and problems in ultrasound-responsive drug delivery systems.Leveraging the power of ultrasound for therapeutic design and optimization.Phase-shift, stimuli-responsive drug carriers for targeted delivery.PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors.Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.Micro- and Nanoparticles for Treating Cardiovascular Disease.Enhanced delivery of PEAL nanoparticles with ultrasound targeted microbubble destruction mediated siRNA transfection in human MCF-7/S and MCF-7/ADR cells in vitro.The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina.Controlled Angiogenesis in Peptide Nanofiber Composite Hydrogels Targeted nanotheranostics for personalized cancer therapy.Nanomedicine strategies for drug delivery to the ear.Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Emerging translational research on magnetic nanoparticles for regenerative medicine.Therapeutic angiogenesis in ischemic muscles after local injection of fragmented fibers with loaded traditional Chinese medicine.Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord.Controlled release of Fe3O4 nanoparticles in encapsulated microbubbles to tumor cells via sonoporation and associated cellular bioeffects.Drug-loaded nano-microcapsules delivery system mediated by ultrasound-targeted microbubble destruction: A promising therapy method.DNA Methyltransferase 1-Dependent DNA Hypermethylation Constrains Arteriogenesis by Augmenting Shear Stress Set Point.Delivery of TFPI-2 using SonoVue and adenovirus results in the suppression of thrombosis and arterial re-stenosis.Coxsackievirus B3 used as a gene therapy vector to express functional FGF2.Enzyme-Targeted Nanoparticles for Delivery to Ischemic Skeletal Muscle.Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease.Design and characterization of hydrogel nanoparticles with tunable network characteristics for sustained release of a VEGF-mimetic peptide.

P2860

Q26830196-3E5D1684-D34D-42A2-B8EB-DB85D39C9D55 Q26866082-E816536A-3C16-46A4-BE07-AC93AF19C99B Q26995026-D2455E40-A369-49C0-BE47-3601D0F7B87A Q28080611-1720BA26-05CC-4B13-8BC8-9491CE41DC3E Q30276705-AA645F03-9CF1-494F-9754-6CB1581D82A9 Q30278047-48755869-FE43-4FA3-965E-74ADBD2C98E4 Q30300837-AA28A124-4D8C-4A6B-A913-8F9A740DF81B Q30368171-82EFD305-D673-4C7D-84F8-449551DCDF96 Q30389310-977A1233-D08D-4953-8172-183B8C8AE661 Q30408398-D1D1C5DC-2811-4727-AA7E-682FD8A69598 Q30410690-FBDEA2CD-91F7-491B-929B-1ACF803A1BF3 Q30417170-24C094CD-0D93-4791-A22C-9B1F33A64F04 Q30423363-E950A75B-1579-48E4-A74D-BD007BABCCCF Q30426977-7116B821-3132-4E7B-8E76-5B39E47108DD Q30449821-68770AA7-7327-4302-B2C2-6682D62A7A99 Q30450131-03BCEC2B-55DB-44E0-941D-B3A425F003C2 Q30454986-6A83E143-C8C9-4D76-8C02-FF344B679CD6 Q30459779-B8382EF5-79CE-42D7-82C0-5C960F55EC67 Q30466278-F9E965AA-B775-4E99-8CC0-C005BC1D3AFB Q30468564-8B0BD7BD-A8AF-4E16-B129-4D83871F07B6 Q34068511-9D02F59C-4C68-4264-80A1-50B25EAA218C Q35801354-4618A440-A020-4683-98C6-CC7DC7F18BE8 Q36015938-1289117B-57D0-41E4-A679-631F26E32F93 Q36022403-CC28295A-2D44-4C22-BC51-4377E4947CAE Q36388879-77799EDD-4CB2-49E6-AFF3-5EC435E525A9 Q36623213-7F955BF5-9B6B-449D-B0F9-5FFC02C1FEA9 Q38054793-CF541AE1-C156-4A06-B29D-A4C147BC681A Q38120319-BBE49288-E24C-4700-A6EF-8F49DA94D8A3 Q38217461-E19D80E6-55C2-4A9C-B030-289D75EE18A3 Q38617021-96DF646B-8200-4030-8B8C-806C40A0CCAD Q38852928-7ABFA1D4-6CB6-44B7-95EE-50F5C3911321 Q39291722-857F53F2-00B0-4770-AF3B-C8A27AEB03B8 Q39581413-D003BAC5-7187-4C26-86B7-1EA49ABBE495 Q42564504-620EF01E-8B57-43D9-B348-384F664ABC91 Q45074404-45C194C1-C746-4147-86E9-077A22763670 Q45862580-A569EFAC-0490-4993-A44B-B66AA50EC3EB Q45875870-75F134F1-5E1B-45D9-8786-633ED1E0B65F Q46269755-4C2EE524-51AF-48B4-B130-1BD0C53E8BAB Q46813976-6428316C-16E4-4644-9024-402334913E10 Q47880097-E2DA94D2-B648-41B6-AA38-DD1172D28FD9

P2860

Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis.

http://www.wikidata.org/entity/Q30438396

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@ast

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@en

type

label

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@ast

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@en

prefLabel

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@ast

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@en

P1433

Q30438396-E0054FBC-3FD0-465B-AF99-06B76E997E57

P1476

Q30438396-145B7207-10ED-4AB8-8571-B3AC4DA41160

P2093

Q30438396-0589DF35-7944-4FA5-8477-D0A1506857CE

Q30438396-22C428A0-D68D-414D-ACDB-8968BE3F7C87

Q30438396-38E4C98B-27E2-4808-94B4-EA927AC1B283

Q30438396-7DEA9A5D-9384-4A0C-B22B-153259B3FA94

P2860

Q30438396-0964DD08-4BC5-400E-BD11-CA6B2EE1986C

Q30438396-0E98EA75-3959-4D38-80BC-A5BCCB816DA4

Q30438396-1BC1E5B9-CABD-4892-B4FA-9A578EFAFF89

Q30438396-23C28B7E-BBE6-45ED-94D3-9C061B178017

Q30438396-245800E7-6B1F-45B8-A660-1567CE713BC9

Q30438396-25C9DEF4-679A-4FE3-A7CA-B688588D4D2B

Q30438396-2A1156F2-D691-48C2-84E0-5B3D89746645

Q30438396-302A15D5-97F1-4183-BF9D-5CCD4EEE8134

Q30438396-34AEC7C7-B8AB-471E-A4B9-B946AB955410

Q30438396-505E2CCE-DDCD-4849-95A0-E2C6C3E2CA1D

P304

Q30438396-ED616FE5-692F-4899-9EC0-3A667D5E9D47

P31

Q30438396-373F0113-93F2-4E1A-BA0C-B3601CF6CCD6

P356

Q30438396-546FDDB0-A4ED-4465-933D-1304CF4E2EF2

P433

Q30438396-B92D2457-12EE-46AC-8D3F-ACB2FAC30159

P478

Q30438396-DFC0E0BD-C40B-498A-89BF-60605B5AC6D4

P50

Q30438396-B1DD977B-B8EC-4C91-A8AA-9AA6C88CC9B3

P577

Q30438396-1B5F361E-E40C-4576-82D6-2BA64EEAFC6A

P5875

Q30438396-065C0E00-3CA9-45C4-BB6F-141C26522B18

P698

Q30438396-E40D7752-C73A-41FB-BEF0-9677E21892A3

P921

Q30438396-D021A730-52DB-40D2-BDDC-3371A58B084A

P932

Q30438396-339B2529-3ABD-4368-BB21-D6B21B10BB10

P356

P1433

P1476

Targeted delivery of nanoparti ...... or therapeutic arteriogenesis.

@en

P2093

Alexander L Klibanov

http://www.w3.org/2001/XMLSchema#string

Caitlin W Burke

http://www.w3.org/2001/XMLSchema#string

Ji Song

http://www.w3.org/2001/XMLSchema#string

Richard J Price

http://www.w3.org/2001/XMLSchema#string

P2860

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

Mechanisms of angiogenesis

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Influence of injection site, microvascular pressure and ultrasound variables on microbubble-mediated delivery of microspheres to muscle.

Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound.

Ultrasound-microbubble-induced neovascularization in mouse skeletal muscle.

Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound.

Microbubble destruction with ultrasound augments neovascularisation by bone marrow cell transplantation in rat hind limb ischaemia.

Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice.

Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb.

P304

1769-1777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SMLL.200800806

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

John C Chappell

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23187404

http://www.w3.org/2001/XMLSchema#string

P698

18720443

http://www.w3.org/2001/XMLSchema#string

P921

P932

2716217

http://www.w3.org/2001/XMLSchema#string